SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Almlöf Martin) srt2:(2020-2024)"

Sökning: WFRF:(Almlöf Martin) > (2020-2024)

  • Resultat 1-8 av 8
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Sanjiv, Kumar, et al. (författare)
  • MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia
  • 2021
  • Ingår i: Cancer Research. - : American Association For Cancer Research (AACR). - 0008-5472 .- 1538-7445. ; 81:22, s. 5733-5744
  • Tidskriftsartikel (refereegranskat)abstract
    • Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, exhibiting high levels of reactive oxygen species (ROS). ROS levels have been suggested to drive leukemogenesis and is thus a potential novel target for treating AML. MTH1 prevents incorporation of oxidized nucleotides into the DNA to maintain genome integrity and is upregulated in many cancers. Here we demonstrate that hematologic cancers are highly sensitive to MTH1 inhibitor TH1579 (karonudib). A functional precision medicine ex vivo screen in primary AML bone marrow samples demonstrated a broad response profile of TH1579, independent of the genomic alteration of AML, resembling the response profile of the standard-of-care treatments cytarabine and doxorubicin. Furthermore, TH1579 killed primary human AML blast cells (CD45+) as well as chemotherapy resistance leukemic stem cells (CD45+Lin−CD34+CD38−), which are often responsible for AML progression. TH1579 killed AML cells by causing mitotic arrest, elevating intracellular ROS levels, and enhancing oxidative DNA damage. TH1579 showed a significant therapeutic window, was well tolerated in animals, and could be combined with standard-of-care treatments to further improve efficacy. TH1579 significantly improved survival in two different AML disease models in vivo. In conclusion, the preclinical data presented here support that TH1579 is a promising novel anticancer agent for AML, providing a rationale to investigate the clinical usefulness of TH1579 in AML in an ongoing clinical phase I trial.
  •  
2.
  • Gyger, Samuel, et al. (författare)
  • Metropolitan single-photon distribution at 1550 nm for random number generation
  • 2022
  • Ingår i: Applied Physics Letters. - : AIP Publishing. - 0003-6951 .- 1077-3118. ; 121:19, s. 194003-
  • Tidskriftsartikel (refereegranskat)abstract
    • Quantum communication networks will connect future generations of quantum processors, enable metrological applications, and provide security through quantum key distribution. We present a testbed that is part of the municipal fiber network in the greater Stockholm metropolitan area for quantum resource distribution through a 20 km long fiber based on semiconductor quantum dots emitting in the telecom C-band. We utilize the service to generate random numbers passing the NIST test suite SP800-22 at a subscriber 8 km outside of the city with a bit rate of 23.4 kbit/s.
  •  
3.
  • Gyger, Samuel, et al. (författare)
  • Metropolitan Single-Photon Distribution at 1550 nm for Random Number Generation
  • 2023
  • Ingår i: 2023 Conference on Lasers and Electro-Optics, CLEO 2023. - : Institute of Electrical and Electronics Engineers Inc..
  • Konferensbidrag (refereegranskat)abstract
    • Quantum communication networks are used for QKD and metrological applications. We present research connecting two nodes ≈ 20 kilometers apart over the municipal fiber network using semiconductor quantum dots emitting at 1550 nm.
  •  
4.
  • Lundtoft, Christian, et al. (författare)
  • Complement C4 Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases
  • 2022
  • Ingår i: Arthritis & Rheumatology. - : Wiley. - 2326-5191 .- 2326-5205. ; 74:8, s. 1440-1450
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective Copy number variation of the C4 complement components, C4A and C4B, has been associated with systemic inflammatory autoimmune diseases. This study was undertaken to investigate whether C4 copy number variation is connected to the autoimmune repertoire in systemic lupus erythematosus (SLE), primary Sjogrens syndrome (SS), or myositis. Methods Using targeted DNA sequencing, we determined the copy number and genetic variants of C4 in 2,290 well-characterized Scandinavian patients with SLE, primary SS, or myositis and 1,251 healthy controls. Results A prominent relationship was observed between C4A copy number and the presence of SSA/SSB autoantibodies, which was shared between the 3 diseases. The strongest association was detected in patients with autoantibodies against both SSA and SSB and 0 C4A copies when compared to healthy controls (odds ratio [OR] 18.0 [95% confidence interval (95% CI) 10.2-33.3]), whereas a weaker association was seen in patients without SSA/SSB autoantibodies (OR 3.1 [95% CI 1.7-5.5]). The copy number of C4 correlated positively with C4 plasma levels. Further, a common loss-of-function variant in C4A leading to reduced plasma C4 was more prevalent in SLE patients with a low copy number of C4A. Functionally, we showed that absence of C4A reduced the individuals capacity to deposit C4b on immune complexes. Conclusion We show that a low C4A copy number is more strongly associated with the autoantibody repertoire than with the clinically defined disease entities. These findings may have implications for understanding the etiopathogenetic mechanisms of systemic inflammatory autoimmune diseases and for patient stratification when taking the genetic profile into account.
  •  
5.
  • Smeds, Patrik, et al. (författare)
  • Hydra-genetics, a modular framework for bioinformatics pipeline development
  • 2024
  • Ingår i: European Journal of Human Genetics. - : Nature Portfolio. - 1018-4813 .- 1476-5438. ; 32:Suppl. 1, s. 675-676
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • Background: Processing information from massively parallel sequencing/next-generation sequencing (NGS) data involves several steps that transform millions of rows of input data into more accessible genetic information. The combination of bioinformatics tools that extract all requested information for a particular clinical/research application, how they are tuned and the order in which they are executed constitute a bioinformatics pipeline. Software is often reused in several pipelines and regularly updated. For clinically validated NGS pipelines it may be challenging when individual components of several pipelines needs updating or when tools are replaced with new applications.Methods: The Hydra-genetics framework takes advantage of version controlled Snakemake modules. Pipeline steps are split into modules that can be configured and tested individually. The modules can be combined to build complete bioinformatics analyses, or be added to existing pipelines. All modules are subjected to extensive testing to ensure that new releases do not unexpectedly break existing pipelines or deviate from guidelines and best practices on how to write code.Results: Bioinformaticians from five Genomics Medicine Sweden centers used Hydra-genetics to develop the bioinformatics pipeline for the comprehensive solid tumor panel, GMS560. The pipeline analyses tumor DNA and/or RNA data and generates information on genetic variation including complex biomarkers such as tumor mutation burden and microsatellite instability. It is validated and in clinical use.Conclusions: The Hydra-genetics framework provides a platform for structured bioinformatics pipeline development and facilitates joint development projects involving multiple partners. It makes clinical pipeline development easier, faster and more structured.
  •  
6.
  • Visnes, Torkild, et al. (författare)
  • Targeting OGG1 arrests cancer cell proliferation by inducing replication stress
  • 2020
  • Ingår i: Nucleic Acids Research. - : Oxford University Press (OUP). - 0305-1048 .- 1362-4962. ; 48:21, s. 12234-12251
  • Tidskriftsartikel (refereegranskat)abstract
    • Altered oncogene expression in cancer cells causes loss of redox homeostasis resulting in oxidative DNA damage, e.g. 8-oxoguanine (8-oxoG), repaired by base excision repair (BER). PARP1 coordinates BER and relies on the upstream 8-oxoguanine-DNA glycosylase (OGG1) to recognise and excise 8-oxoG. Here we hypothesize that OGG1 may represent an attractive target to exploit reactive oxygen species (ROS) elevation in cancer. Although OGG1 depletion is well tolerated in non-transformed cells, we report here that OGG1 depletion obstructs A3 T-cell lymphoblastic acute leukemia growth in vitro and in vivo, validating OGG1 as a potential anti-cancer target. In line with this hypothesis, we show that OGG1 inhibitors (OGG1i) target a wide range of cancer cells, with a favourable therapeutic index compared to non-transformed cells. Mechanistically, OGG1i and shRNA depletion cause S-phase DNA damage, replication stress and proliferation arrest or cell death, representing a novel mechanistic approach to target cancer. This study adds OGG1 to the list of BER factors, e.g. PARP1, as potential targets for cancer treatment.
  •  
7.
  • Zhang, Si Min, et al. (författare)
  • Development of a chemical probe against NUDT15
  • 2020
  • Ingår i: Nature Chemical Biology. - : Springer Science and Business Media LLC. - 1552-4450 .- 1552-4469. ; 16:10, s. 1120-1128
  • Tidskriftsartikel (refereegranskat)abstract
    • The NUDIX hydrolase NUDT15 was originally implicated in sanitizing oxidized nucleotides, but was later shown to hydrolyze the active thiopurine metabolites, 6-thio-(d)GTP, thereby dictating the clinical response of this standard-of-care treatment for leukemia and inflammatory diseases. Nonetheless, its physiological roles remain elusive. Here, we sought to develop small-molecule NUDT15 inhibitors to elucidate its biological functions and potentially to improve NUDT15-dependent chemotherapeutics. Lead compound TH1760 demonstrated low-nanomolar biochemical potency through direct and specific binding into the NUDT15 catalytic pocket and engaged cellular NUDT15 in the low-micromolar range. We also employed thiopurine potentiation as a proxy functional readout and demonstrated that TH1760 sensitized cells to 6-thioguanine through enhanced accumulation of 6-thio-(d)GTP in nucleic acids. A biochemically validated, inactive structural analog, TH7285, confirmed that increased thiopurine toxicity takes place via direct NUDT15 inhibition. In conclusion, TH1760 represents the first chemical probe for interrogating NUDT15 biology and potential therapeutic avenues.
  •  
8.
  • Zhang, Si Min, et al. (författare)
  • NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir
  • 2021
  • Ingår i: Cell Chemical Biology. - : Elsevier BV. - 2451-9456 .- 2451-9448. ; 28:12, s. 1693-1702
  • Tidskriftsartikel (refereegranskat)abstract
    • Ganciclovir (GCV) is the first-line therapy against human cytomegalovirus (HCMV), a widespread infection that is particularly dangerous for immunodeficient individuals. Closely resembling deoxyguanosine triphosphate, the tri-phosphorylated metabolite of GCV (GCV-TP) is preferentially incorporated by the viral DNA polymerase, thereby terminating chain extension and, eventually, viral replication. However, the treatment outcome of GCV varies greatly among individuals, therefore warranting better understanding of its metabolism. Here we show that NUDT15, a Nudix hydrolase known to metabolize thiopurine triphosphates, can similarly hydrolyze GCV-TP through biochemical studies and co-crystallization of the NUDT15/GCV-TP complex. More critically, GCV efficacy was potentiated in HCMV-infected cells following NUDT15 depletion by RNAi or inhibition by an in-house-developed, nanomolar NUDT15 inhibitor, TH8321, suggesting that pharmacological targeting of NUDT15 is a possible avenue to improve existing anti-HCMV regimens. Collectively, the data further implicate NUDT15 as a broad-spectrum metabolic regulator of nucleoside analog therapeutics, such as thiopurines and GCV.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-8 av 8
Typ av publikation
tidskriftsartikel (7)
konferensbidrag (1)
Typ av innehåll
refereegranskat (7)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
Helleday, Thomas (4)
Almlöf, Jonas (4)
Stenmark, Pål (3)
Loseva, Olga (2)
Llosera, Gemma Vall (2)
Altun, Mikael (2)
visa fler...
Steinhauer, Stephan (2)
Hammar, Mattias, 196 ... (2)
Östling, Päivi (1)
Henriksson, Martin (1)
Lehmann, Sören (1)
Kozyrev, Sergey V. (1)
Gunnarsson, Iva (1)
Svenungsson, Elisabe ... (1)
Jönsen, Andreas (1)
Leonard, Dag, 1975- (1)
Eloranta, Maija-Leen ... (1)
Lindblad-Toh, Kersti ... (1)
Mandl, Thomas (1)
Nordmark, Gunnel (1)
Wahren-Herlenius, Ma ... (1)
Nilsson, Bo (1)
Rönnblom, Lars (1)
Benitez, Javier (1)
Ladenvall, Claes (1)
Sjöwall, Christopher (1)
Eriksson, Per (1)
Andersson, Helena (1)
Blom, Anna M. (1)
Lundbäck, Thomas (1)
Diaz-Gallo, Lina-Mar ... (1)
Lundberg, Ingrid E. (1)
Rantapää-Dahlqvist, ... (1)
Knapp, Stefan (1)
Landazuri, Natalia (1)
Forsblad d'Elia, Hel ... (1)
Bengtsson, Anders A. (1)
Sandling, Johanna K. (1)
Syvänen, Ann-Christi ... (1)
Axelsson, Hanna (1)
El-Andaloussi, Samir (1)
Munters, Arielle (1)
Krokan, Hans E (1)
Omdal, Roald (1)
Jonsson, Roland (1)
Melin, Malin (1)
Baecklund, Eva, 1956 ... (1)
Bekkhus, Tove (1)
Martin, Myriam (1)
Boström, Johan (1)
visa färre...
Lärosäte
Karolinska Institutet (5)
Stockholms universitet (4)
Lunds universitet (4)
Kungliga Tekniska Högskolan (2)
Uppsala universitet (2)
Göteborgs universitet (1)
visa fler...
Umeå universitet (1)
Örebro universitet (1)
Linköpings universitet (1)
visa färre...
Språk
Engelska (8)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (5)
Naturvetenskap (3)
Teknik (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy